Angela Vincent, MDS 2019 – Autoimmune movement disorders
It was an absolute pleasure to meet with Angela Vincent, Emeritus Professor of Neuroimmunology at the University of Oxford. Until 2016 she led the clinical and research laboratory at Oxford specialising in antibody-mediated neurological diseases. Despite not being a neurologist herself, she spoke from long experience of helping to identify and characterise pathogenic antibodies in patients with movement and other disorders. The views expressed are her own.
1. What are the major challenges in the diagnosis and treatment of autoimmune movement disorders? (0:05)
2. What are the most common clinical presentations of autoimmune movement disorders? (2:47)
3. How have recent advances helped us understand the molecular mechanisms underlying autoimmune movement disorders? (4:07)
4. Which are the most important neuronal autoantibodies in terms of diagnosis and prognosis? (7:10)
Speaker disclosure: Angela Vincent receives a proportion of royalties from Euroimmun AG for LGI1 and CASPR2 antibody assays.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Neuroimmunology
Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]
Michael Levy, AAN 2023: Phase 3 CHAMPION-NMOSD subgroup analyses in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
CHAMPION-NMOSD (NCT04201262) is a study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Ravulizumab binds to the same complement component 5 epitope as eculizumab; however, its longer elimination half-life extends the dosing interval (every 8 versus 2 weeks). In this touchNEUROLOGY interview, we caught up with Dr Michael Levy (Massachusetts General Hospital, […]
Sean Pittock, ECTRIMS 2022: Subgroup analyses from the phase 3 CHAMPION-NMOSD investigating ravulizumab for neuromyelitis optica spectrum disorder
The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the pre-specified efficacy analyses in clinically relevant patient subgroups, and the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!